Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| latanoprost 0.005% (Xalatan) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and the health care utilization in the two treatment groups over 36 months. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Ekenäs | Finland | ||||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Helsinki |
| 00100 |
| Finland |
| Pfizer Investigational Site | Helsinki | 00700 | Finland |
| Pfizer Investigational Site | Kuopio | 70100 | Finland |
| Pfizer Investigational Site | Lahti | 15110 | Finland |
| Pfizer Investigational Site | Rovaniemi | 96200 | Finland |
| Pfizer Investigational Site | Seinäjoki | 60100 | Finland |
| Pfizer Investigational Site | Tampere | 33100 | Finland |
| Pfizer Investigational Site | Turku | 20100 | Finland |
| Pfizer Investigational Site | Jönköping | 551 85 | Sweden |
| Pfizer Investigational Site | Karlstad | 652 20 | Sweden |
| Pfizer Investigational Site | Kristianstad | 291 31 | Sweden |
| Pfizer Investigational Site | Linköping | Sweden |
| Pfizer Investigational Site | Ludvika | 771 81 | Sweden |
| Pfizer Investigational Site | Mölndal | Sweden |
| Pfizer Investigational Site | Nacka | 131 83 | Sweden |
| Pfizer Investigational Site | Norrköping | 601 82 | Sweden |
| Pfizer Investigational Site | Norrköping | 602 36 | Sweden |
| Pfizer Investigational Site | Nyköping | Sweden |
| Pfizer Investigational Site | Örebro | 70361 | Sweden |
| Pfizer Investigational Site | Seinajoki | 151 72 | Sweden |
| Pfizer Investigational Site | Stockholm | 113 22 | Sweden |
| Pfizer Investigational Site | Stockholm | Sweden |
| Pfizer Investigational Site | Sundsvall | 851 86 | Sweden |
| Pfizer Investigational Site | Täby | 183 34 | Sweden |
| Pfizer Investigational Site | Uppsala | 751 85 | Sweden |
| Pfizer Investigational Site | Uppsala | Sweden |
| ID | Term |
|---|---|
| D009798 | Ocular Hypertension |
| D005902 | Glaucoma, Open-Angle |
| ID | Term |
|---|---|
| D005128 | Eye Diseases |
| D005901 | Glaucoma |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077338 | Latanoprost |
| ID | Term |
|---|---|
| D011461 | Prostaglandins F, Synthetic |
| D011465 | Prostaglandins, Synthetic |
| D011453 | Prostaglandins |
| D015777 | Eicosanoids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |
Not provided
Not provided